Role
Scott main responsibilities are to provide flow cytometry expertise and support both internal and external projects performed at the John van Geest Cancer Research Centre, but also for the wider university. He currently supports several research projects in the following areas; cancer, immunology and metabolism.
If you require any flow cytometry support for your research projects, feel free to get in contact with him.
Career overview
Scott completed his BSc in Biomedical Science at Nottingham Trent University with a placement year at LGC Ltd in Cambridgeshire. He then went on to complete his MSc in Cancer Immunology and Biotechnology at The University of Nottingham.
Following his studies, he worked in several positions within the biotechnology field, focusing on protein sciences at Albumedix Ltd and assay development projects at F-star Therapeutics Ltd. During this time, he was heavily involved in conducting pharmacokinetic (PK) and immunogenicity (IG) studies of new bispecific antibodies aimed at treating various disease areas such as cancer and autoimmune diseases.
Scott then moved to Leeds to pursue his PhD in the Brain Metastasis Research Group, where he investigated whether the overexpression of specific chemokine receptors (CR) could improve the trafficking of T cells towards melanoma brain metastases and enhance the efficacy of immune checkpoint inhibitors.
After completing his PhD, Scott moved to the National Measurement Laboratories (NML) in Leeds, where he validated new flow cytometry protocols to contribute to both preclinical and clinical projects in various research areas such as cancer, immunology, and cardiovascular science.
Scott then returned to Nottingham and took up a Research Assistant post at the John van Geest Cancer Research Centre, where he provided expertise in flow cytometry to support both internal and external projects at NTU in areas such as cancer and immunology.
Research areas
Scott research interests are around cancer immunology, T cell biology, lentiviral vectors, gene therapy, ex-vivo models, cancer mouse models, assay development and validation, genetic engineering of immune cells.
Publications
Fife C, Williams J, James F, Gregory S, Andreou T, Sunderland A, McKimmie C, Brownlie RJ, Salmond RJ, Heaton S, Errington-Mais F, Hadi Z, Westhead DR, Hall M, Davie A, Emmett A, Lorger M. Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases. J Immunother Cancer. 2024 Nov 17;12(11):e009522. doi: 10.1136/jitc-2024-009522. PMID: 39551601; PMCID: PMC11574513. https://pmc.ncbi.nlm.nih.gov/articles/PMC11574513/